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PD4-2-8 Cytotoxic Chemotherapy I, Tue, 16:00 - 17:30
Advanced age is associated with lack of administration of adjuvant 
chemotherapy for completely resected stage IB-III non-small cell 
lung cancer (NSCLC)
Riely, Gregory J.; Seshan, V. E.; Azzoli, C. G.; Kris, Mark G.; Rusch, 
Valerie W.; Park, Bernard K. 
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: The number of elderly NSCLC patients continues to 
rise. Adjuvant chemotherapy for patients with resected early-stage 
NSCLC improves overall survival. However, individuals ≥70 years old 
represented just 9% of patients in the LACE meta-analysis of adjuvant 
chemotherapy trials in NSCLC (Pignon et al ASCO 2006). We sought 
to identify factors, including age, associated with administration of 
adjuvant chemotherapy.
Methods: A retrospective review of a prospective surgical database 
was performed to identify patients who underwent complete resection 
of a pathologic stage IB-III NSCLC between June 2003 and December 
2005. Patients who received preoperative therapy were excluded. 
Results: A total of 389 eligible patients were identiﬁed with a median 
age of 69 years (range 33-88). Thirty-three percent (130/389) received 
adjuvant chemotherapy. Patient characteristics are shown in the Table. 
Twenty-four percent of patients ≥70 years old received adjuvant chemo-
therapy. There was no association between receiving adjuvant chemo-
therapy and presence of medical comorbidities (CAD, CHF, HTN, any 
cardiac comorbidity, diabetes), smoking history, or type of surgical pro-
cedure (pneumonectomy, lobectomy, segmentectomy, wedge resection). 
Advancing age (p=0.002 for age ≥65, p=0.0003 for age ≥70) and pres-
ence of pathologic stage IB (p<0.0001) disease were associated with not 
receiving adjuvant chemotherapy. Controlling for stage, age was the most 
important predictor of whether patients received adjuvant chemotherapy. 
Twenty-four percent of patients ≥70 received adjuvant chemotherapy.
Conclusions: Advancing age and presence of pathologic stage IB 
disease are associated with lack of administration of adjuvant chemo-
therapy for resected NSCLC. Reasons, such as patient preference and 
clinician bias need further elucidation.
Characteristic no adjuvant chemo (n=263)
adjuvant chemo 
(n=126) p value
Stage
IB 160 (61%) 33 (26%) <0.0001
IIA 15 (6%) 18 (14%)  
IIB 35 (13%) 22 (17%)  
IIIA 33 (13%) 45 (36%)  
IIIB 20 (8%) 8 (6%)  
Median Age (range) 70 (33-87) 65 (35-88) <0.001
Cardiac Comorbidities 144 (55%) 60 (48%) 0.2
COPD 75 (29%) 23 (18%) 0.03
Diabetes 36 (14%) 9 (7%) 0.06
Kidney Disease 4 (2%) 0 (0%) 0.3
Former Smoker 241 (92%) 112 (89%) 0.5
Never Smoker 22 (8%) 14 (11%)  
Lobectomy 213 (81%) 103 (82%) 0.89
Pneumonectomy 14 (5%) 15 (12%) 0.037
Sublobar Resection 36 (14%) 8 (6%) 0.039
PD4-3-1 Cytotoxic Chemotherapy II, Tue, 16:00 - 17:30
Pretreatment hemoglobin level is a prognostic indicator in patients 
with non-small-cell lung cancer
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Objectives: To investigate the correlation between the hemoglobin 
levels, other clinicpathologic factors, and survival time.
Methods: Anemia is deﬁned as a HB level <12.0g/dl in men and 
<11.0g/dl in women. 454 patients with non-small-cell lung cancer 
treated in the Shanghai Chest Hospital from November 2003 to March 
2005 were retrospectively analyzed. Survival analysis was evaluated by 
Kaplan-Meier and Log-Rank test. Multivariate analysis was performed 
by Cox Stepwise Regression model. The correlation of the HB level 
with survival was performed by linear regression. The HB levels were 
obtained at the initial visit to our hospital. 
Results: The median survival time for all of these patients 28.17 
months, 1-year survival rate was 73.13%. Of these, 150(33%) pa-
tients had anemia and 304(67%) patients without anemia. The median 
survival time for the patients with anemia was 20.75m; patients without 
anemia 33.14m. The 1-year survival rate was signiﬁcantly lower in 
patients with anemia than in without anemia (64%vs 77.63%, p=0.002). 
The linear regression showed a signiﬁcantly correlation between the 
HB levels with the survival time(p=0.049). In subset, the HB level of 
the patients in stage III and in male were also shown correlative with 
the survival time(p=0.03;0.01;respectively), but in stage I, II, IV or in 
female were no signiﬁcantly correlation. And the Cox Stepwise Regres-
sion analysis showed that anemia was a independent prognostic factor 
inﬂuencing survival.
Conclusion: Patients without anemia have signiﬁcantly higher survival 
rate. The HB level appears to be a signiﬁcant independent prognostic 
indicator in patients with lung cancer.
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ACTION (Assessment of Costs and ouTcomes of chemotherapy In an 
Observational setting in patients with advanced NSCLC) is a prospec-
tive, pan-European observational study. The objective of ACTION is to 
describe advanced NSCLC treatment patterns and patient outcomes in 
routine clinical practice.
Methods: Chemonaive patients (pts) aged ≥18 yrs with stage IIIb/IV 
NSCLC were observed for 18 months from presentation for initiation 
of ﬁrst line chemotherapy (CT). All pt care, including CT given, was at 
the discretion of the pt/physician. WHO Performance Status (PS) was 
recorded at each observation: baseline, after 2 cycles of ﬁrst line CT, at 
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the end of 1st line CT, at the initiation and completion of second line 
CT and 12 and 18 months post baseline.
Results: 975 patients were enrolled between April 2003 and Sep-
tember 2004, with observations completed in March 2006. Median 
age was 65 yrs (32-90) with 28.3% of pts aged ≥ 70 yrs; 71.3% were 
male; 65.2% had stage IV disease. 487 pts experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT (79 
pts, 15.3% unknown). Overall baseline WHO PS was 0 (21.1%), 1 
(65.1%), 2 (10.0%), 3 (3.3%), 4 (0.5%). After 2 cycles of CT, WHO 
PS was unchanged for 57.6% (562) of pts (missing 99 pts); analysis by 
baseline WHO PS showed no change for 90 (44.3%) of pts with PS 0, 
423 (67.6%) PS 1, 32 (33.3%) PS 2, 14 (43.8%) PS 3 and 3 pts (60.0%) 
with baseline PS 4. Median duration of ﬁrst line CT was 3.0 months. At 
the end of 1st line chemotherapy PS was unchanged from baseline for 
41.2% of pts (missing 223 pts, 22.9%). Analysis by baseline PS shows 
no change for 64 (31.5%) of pts with baseline PS 0, 313 (50.0%) PS 1, 
14 (14.6%) PS 2, 9 (28.1%) PS 3, 2 (40%) PS 4. Improvement in PS 
during 1st line CT was seen in 66 (10.5%) of pts with baseline PS 1, 30 
(31.3%) PS 2, 5 (15.6%) PS 3, 2 (40%) PS 4. 285 pts were intended to 
receive 2nd line CT. At initiation of 2nd line CT, overall WHO PS was 
0 (11.3%), 1 (67.5%), 2 (17%), 3 (3.9%), 4 (0.4%). Median duration 
of 2nd line CT was 2.5 months. At the end of 2nd line CT, 254 patients 
had WHO PS 0 (6.8%), 1 (56.2%), 2 (17%), 3 (14.5%), 4 (5.5%) (no 
data 19 pts). 
Conclusion: The administration of CT to patients with PS 0 - 4 was 
recorded in this ﬁrst large-scale observational study of pts with ad-
vanced NSCLC. The majority of patients maintain PS after two cycles 
of 1st line CT. In those pts who received second line CT, a trend toward 
deteriorating PS is seen. The assessment of WHO PS is subjective. 
Maintenance or change in WHO PS may be driven by the impact of the 
cancer, chemotherapy treatment and/or any pre-existing co-morbidities. 
PD4-3-3 Cytotoxic Chemotherapy II, Tue, 16:00 - 17:30
Phase II trial of carboplatin plus docetaxel combined with a 
selective cyclooxygenase-2 inhibitor (meloxicam) in first-line 
treatment of patients with advanced unresectable non-small cell 
lung cancer: anti-tumor effect and cyclooxygenase-2 expression
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Background: Preclinical and clinical studies showed that selective 
cyclooxygenase-2 (COX-2) inhibitor (celecoxib or rofecoxib) might 
improve efﬁcacy of treatment of advanced NSCLC. Meloxicam is 
a non-coxib, non-steroidal anti-inﬂammatory drug (NSAID), and 
selectively inhibits COX-2. Comparing with coxibs, meloxicam shows 
less cardiovascular toxicity; however, anti-tumor efﬁcacy has not been 
proved in clinical settings. The correlation between overexpression of 
COX-2 and chemotherapeutic response is also still controversial.
Methods: Eligibility criteria included stage IIIB/IV histologically or 
cytologically conﬁrmed non-small cell lung cancer, no prior chemo-
therapy, no current use of NSAIDs, PS = 0-1, and no urgent symptoms. 
Patients received oral meloxicam (150 mg) daily, and carboplatin 
(AUC 5) plus docetaxel (60 mg/m2) on day 1, every 3 weeks. Treat-
ment was continued until disease progression or toxicity. The primary 
endpoint was anti-tumor effect, with secondary endpoints including 
the safety. Calculated sample size was 45 patients (Simon’s two-stage 
minimax design). Tumor immunohistochemistry was performed for 
COX-2 and p27 in archival parafﬁn-embedded pre-treatment tumor tis-
sues. A semi-quantitative expression score was calculated on the basis 
of both percentage of positive tumor staining (COX-2 in cytoplasm, 
and p27 in cell nuclei) and staining intensity.
Results: From April 2005 to July 2006, a total of 50 patients (33 
males/17 females; median age, 65 years; ECOG PS, 0/1 = 24/26; tumor 
histology, adeno/squamous/other = 29/18/3; stage, IIIB/IV/recurrence 
= 16/32/2) were accrued and 47 patients were eligible. Partial response 
was 40% (95% CI 25-55%), stable disease was 38% (95% CI 23-
53%), and 19% had progressive disease. Grade 3/4 hematologic events 
included leukopenia (81%), neutropenia (96%), and thrombocytopenia 
(8%). Grade 3/4 non-hematologic events included hyponatremia (6%), 
anorexia (6%), fatigue (2%), angina (2%), skin rash (2%), and neuropa-
thy (2%). Febrile neutropenia occurred in 2 patients, and one patient 
developed pneumonia. Tumor tissues were available from 34 patients, 
and 32 samples were sufﬁcient for analysis. COX-2 expression corre-
lated with response rate (PR/SD+PD = 7/4 in high COX-2 score group, 
and 3/11 in low COX-2 score group; p<0.05, chi-square test). Response 
rate was not correlated with p27 status. There was no statistical associa-
tion between COX-2 and p27 expression.
Conclusions: Meloxicam added to carboplatin and docetaxel demon-
strated acceptable tolerability with encouraging activity in advanced 
NSCLC patients, especially in the patients with high COX-2 expres-
sion.
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relationships (ERRs) to clinical study results from western and 
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Background: The efﬁcacy of PEM 500mg/m2 administered with 
vitamin B12 and folic acid (FS) in previously treated NSCLC has been 
established (Hanna 2004, N=571 [Study-W0]). The 500mg/m2 dose 
used in that study was selected based on the MTD for single-agent 
PEM without FS. Subsequent phase I studies in both western and 
Japanese study populations showed that single-agent PEM with FS was 
tolerated at doses of 900-1000mg/m2. The low toxicities in Study-W0 
and the tolerability of higher doses in the more recently completed dose 
escalation studies with FS led to studies comparing PEM 500mg/m2 to 
900 mg/m2 or 1000mg/m2 to determine whether a higher dose would 
provide additional efﬁcacy while maintaining an acceptable safety 
proﬁle. This work examines PEM ERRs and clinical study results from 
trials conducted in western and Japanese patients.
